"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

Lenny Santoro was diagnosed with prostate cancer in 2011. Thanks to clinical trials Santoro participated in at the Duke ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...